Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAllison M. BockSGSharmila GiriGNGrzegorz S. Nowakowski

Discussion

Loading...

Member takes

Overview

Randomized trial examines epcoritamab vs observation for patients with partial response after CAR-T, indicating potential for improved outcomes.

Key Points

  • Epcoritamab was found to improve complete response rates in patients post CAR-T, suggesting a promising treatment option.
  • The study targets a population of up to 120 patients who achieved a partial response after CAR-T therapy.
  • Multicenter, open-label trial investigates efficacy and safety of epcoritamab compared to observation following CAR-T treatment.
  • Findings may highlight the role of bispecific antibodies in enhancing management of relapsed large B-cell lymphomas.

Cite This Study

Bock et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d600https://doi.org/10.1182/blood-2025-3748
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab2025
  2. 2Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma2025
  3. 3Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder2025
  4. 4Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma2025 · 1 citations
  5. 5Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study2025